Acadian Asset Management LLC Aptinyx Inc. Transaction History

Acadian Asset Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$0.06 - $0.14 $9,303 - $21,708	-155,061 Reduced 40.88%	224,265 $16,000
Q1 2023 May 11, 2023	BUY	$0.12 - $0.69 $30,305 - $174,258	252,549 Added 199.21%	379,326 $46,000
Q3 2022 Nov 14, 2022	BUY	$0.35 - $0.72 $23,587 - $48,522	67,392 Added 113.48%	126,777 $45,000
Q2 2022 Aug 09, 2022	BUY	$0.38 - $2.58 $22,566 - $153,213	59,385 New	59,385 $33,000
Q1 2021 May 11, 2021	SELL	$2.86 - $4.33 $199,350 - $301,813	-69,703 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$2.93 - $4.3 $457,888 - $671,986	-156,276 Reduced 69.16%	69,703 $241,000
Q3 2020 Nov 09, 2020	SELL	$3.05 - $4.99 $78,107 - $127,788	-25,609 Reduced 10.18%	225,979 $765,000
Q2 2020 Aug 12, 2020	BUY	$1.99 - $4.4 $107,475 - $237,635	54,008 Added 27.33%	251,588 $1.05 Million
Q1 2020 May 11, 2020	BUY	$1.81 - $5.03 $153,815 - $427,454	84,981 Added 75.47%	197,580 $427,000
Q4 2019 Feb 06, 2020	BUY	$2.84 - $4.25 $13,739 - $20,561	4,838 Added 4.49%	112,599 $385,000
Q3 2019 Nov 07, 2019	BUY	$3.0 - $4.08 $148,284 - $201,666	49,428 Added 84.73%	107,761 $376,000
Q2 2019 Aug 08, 2019	BUY	$2.95 - $4.38 $172,082 - $255,498	58,333 New	58,333 $195,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.